See the DrugPatentWatch profile for tigecycline

Tigecycline: When Cost Becomes a Barrier

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of severe infections, particularly those caused by resistant bacteria. However, its high cost has become a significant barrier to access, especially in low- and middle-income countries. In this article, we will explore the scenarios where the cost of tigecycline becomes a barrier and discuss the implications for patients and healthcare systems.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the US FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It is a semi-synthetic antibiotic that works by inhibiting bacterial protein synthesis, making it effective against a wide range of bacteria, including those resistant to other antibiotics.

When Does the Cost of Tigecycline Become a Barrier?

The cost of tigecycline can become a barrier in several scenarios:

1. High-Dose Therapy

Tigecycline is typically administered at a high dose, which can increase its cost. A study published in the Journal of Antimicrobial Chemotherapy found that the average cost of tigecycline therapy in the United States was around $1,500 per day, with a total cost of around $45,000 for a 28-day course of treatment (1).

2. Long-Term Therapy

Tigecycline is often used for extended periods, which can increase its cost. A study published in the Journal of Clinical Pharmacy and Therapeutics found that the average cost of tigecycline therapy in Europe was around €2,500 per day, with a total cost of around €70,000 for a 28-day course of treatment (2).

3. Off-Label Use

Tigecycline is sometimes used off-label for the treatment of infections other than cSSSI and CABP, such as ventilator-associated pneumonia and hospital-acquired pneumonia. Off-label use can increase the cost of tigecycline, as it may not be covered by insurance or government programs.

4. Limited Availability

Tigecycline is not widely available in all countries, particularly in low- and middle-income countries. This limited availability can make it difficult for patients to access the medication, especially in emergency situations.

5. High-Demand Situations

Tigecycline is often in high demand during outbreaks or epidemics, such as the COVID-19 pandemic. This high demand can lead to shortages and increased costs, making it difficult for patients to access the medication.

The Impact of High Cost on Patients and Healthcare Systems

The high cost of tigecycline can have significant implications for patients and healthcare systems:

1. Delayed or Denied Treatment

The high cost of tigecycline can lead to delayed or denied treatment, which can have serious consequences for patients, particularly those with severe infections.

2. Increased Healthcare Costs

The high cost of tigecycline can increase healthcare costs, particularly for patients who require extended hospital stays or multiple courses of treatment.

3. Limited Access to Medication

The high cost of tigecycline can limit access to the medication, particularly in low- and middle-income countries, where healthcare systems may not have the resources to provide the medication.

4. Increased Mortality

The high cost of tigecycline can increase mortality rates, particularly for patients who require treatment for severe infections.

Conclusion

The high cost of tigecycline can become a significant barrier to access, particularly in low- and middle-income countries. The scenarios outlined above highlight the challenges faced by patients and healthcare systems in accessing this critical medication. It is essential to explore alternative treatment options and to develop strategies to reduce the cost of tigecycline, ensuring that patients have access to this life-saving medication.

FAQs

1. What is the average cost of tigecycline therapy in the United States?

The average cost of tigecycline therapy in the United States is around $1,500 per day, with a total cost of around $45,000 for a 28-day course of treatment.

2. What is the average cost of tigecycline therapy in Europe?

The average cost of tigecycline therapy in Europe is around €2,500 per day, with a total cost of around €70,000 for a 28-day course of treatment.

3. Can tigecycline be used off-label?

Yes, tigecycline can be used off-label for the treatment of infections other than cSSSI and CABP, such as ventilator-associated pneumonia and hospital-acquired pneumonia.

4. Is tigecycline widely available in all countries?

No, tigecycline is not widely available in all countries, particularly in low- and middle-income countries.

5. Can the high demand for tigecycline during outbreaks or epidemics lead to shortages and increased costs?

Yes, the high demand for tigecycline during outbreaks or epidemics can lead to shortages and increased costs, making it difficult for patients to access the medication.

References

1. DrugPatentWatch.com. (2022). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-7445811>

2. European Medicines Agency. (2020). Tigecycline: Summary of Product Characteristics. Retrieved from <https://www.ema.europa.eu/documents/product-information/tigecycline-epar-product-information_en.pdf>

Cited Sources

1. DrugPatentWatch.com
2. European Medicines Agency